A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

SecuraBio129 enrolled

Overview

This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).

This was an open-label, single-arm safety and efficacy study of duvelisib administered orally to participants who had been diagnosed with iNHL whose disease was refractory to rituximab and to either chemotherapy or RIT. Approximately 120 participants received 25 milligrams of duvelisib twice daily over the course of 28-day treatment cycles for up to 13 cycles. After completing 13 treatment cycles of duvelisib, participants continued to receive additional cycles of duvelisib until disease progression or unacceptable toxicity. However, to receive additional cycles of duvelisib beyond 13 cycles, participants must have had evidence of response (complete response \[CR\] or partial response \[PR\]) or stable disease according to the International Working Group criteria by the end of Cycle 13.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

129

Conditions

Indolent Non-Hodgkin Lymphoma

Interventions

DuvelisibDRUG

Phosphoinositide-3-kinase (PI3K) inhibitor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants who had been diagnosed with iNHL that had progressed. * Participants must have exhibited lack of CR or progressive disease (PR) or progression within 6 months after the last dose of a chemotherapy induction regimen or RIT. * Participants must have had rituximab-refractory disease, defined as lack of CR or PR or PD within 6 months of last dose. * Measurable disease with a lymph node or tumor mass ≥1.5 centimeters in at least one dimension by computed tomography (CT), positron emission tomography/CT or magnetic resonance imaging. * Adequate renal and hepatic function. Exclusion Criteria: * Candidate for potentially curative therapies in the opinion of the investigator. * Previous treatment with a PI3K inhibitor or Bruton's tyrosine kinase inhibitor. * Prior history of allogeneic hematopoietic stem cell transplant. * Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug. * Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma. * Symptomatic central nervous system NHL. * Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment. * Prior, current, or chronic hepatitis B or hepatitis C infection, positive result for hepatitis C virus antibodies, hepatitis B surface antigen, or hepatitis B core antibodies. * History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.

Locations (69)

Outcomes

Primary Outcomes

Overall Response Rate (ORR)

ORR, defined as the total percentage of participants who had a best overall response of either complete response (CR) or partial response (PR), was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma. ORR is reported with a 2-sided 95% exact confidence interval.

Time frame: Every 8-16 weeks while on treatment with duvelisib for up to 72 months

Secondary Outcomes

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any adverse event that emerged or worsened in the period from the first dose of study treatment to 30 days after the last dose of study treatment. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame: Every 2-8 weeks for up to 73 months

Duration of Response (DOR)

DOR, defined as the time from the first documentation of response to either progressive disease (PD) or death due to any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

Time frame: Every 8-16 weeks for up to 72 months

Progression-free Survival (PFS)

PFS, defined as the time from the first dose of study treatment to the first documentation of either Investigator-assessed PD or death resulting from any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

Time frame: Every 8-16 weeks for up to 72 months

Overall Survival (OS)

OS, defined as the time from the first dose of study treatment to the date of death, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Whittier, California, United States

Unnamed facility

Denver, Colorado, United States

Unnamed facility

Fort Myers, Florida, United States

Unnamed facility

St. Petersburg, Florida, United States

Unnamed facility

Tallahassee, Florida, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Chicago, Illinois, United States

Unnamed facility

Louisville, Kentucky, United States

Unnamed facility

Baltimore, Maryland, United States

...and 59 more locations